Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 8/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27778277 | 0.86 | F10 (0.49) | NPC1TAS1R3TAS1R1TAS1R2CCR3 | |
| SCHEMBL14368809 | 0.86 | F10 (0.49) | NPC1TAS1R3TAS1R1TAS1R2CCR3 | |
| SCHEMBL27757451 | 0.81 | CCR3 (0.48) | NPC1RAB9ACCR3 | |
| SCHEMBL14368778 | 0.81 | TAS1R3 (0.49) | RAB9ASMN1; SMN2HPGDTAS1R3TAS1R1 | |
| SCHEMBL28944630 | 0.81 | TAS1R3 (0.49) | RAB9ASMN1; SMN2HPGDTAS1R3TAS1R1 | |
| SCHEMBL14392662 | 0.80 | CCR3 (0.44) | CCR3 | |
| SCHEMBL14392352 | 0.75 | CHRNA7 (0.51) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14368703 | 0.75 | CHRNA7 (0.51) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14368669 | 0.75 | SSTR3 (0.55) | NPC1RAB9ACCR3SSTR3 | |
| SCHEMBL27757300 | 0.75 | CHRNA7 (0.51) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | NPC1 1012/4885RAB9A 913/4885SMN1; SMN2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.